Last update 21 Nov 2024

Guanfacine hydrochloride

Overview

Basic Info

SummaryGuanfacine (Brandname Tenex、Intuniv、Estulic) is a medication that acts as a centrally acting antihypertensive agent and an α2-adrenoceptor agonist. Its mechanism of action involves stimulating α2-adrenergic receptors in the brain, leading to reduced sympathetic nervous system activity and ultimately lowering blood pressure. Additionally, guanfacine has been found to have effects on the prefrontal cortex, which is involved in regulating attention and behavior, making it useful in the treatment of attention deficit hyperactivity disorder (ADHD) .Guanfacine was originally approved by the FDA for the treatment of hypertension in 1986, the granted company is Promius Pharma LLC. Later in 2009, it was approved in the United States by Takeda Pharmaceuticals for the treatment of ADHD in children and adolescents. It is currently approved in multiple countries around the world.
Drug Type
Small molecule drug
Synonyms
Connexyn, Guanfacine hydrochloride (JAN/USP), Intuniv XR
+ [9]
Mechanism
adrenergic receptor agonists(Adrenergic receptors agonists)
Therapeutic Areas
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (27 Oct 1986),
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC9H9Cl2N3O
InChIKeyINJOMKTZOLKMBF-UHFFFAOYSA-N
CAS Registry29110-47-2
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Attention Deficit Disorder With Hyperactivity
US
02 Sep 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anxiety, SeparationPreclinical
US
04 Jan 2012
Generalized anxiety disorderPreclinical
US
04 Jan 2012
Phobia, SocialPreclinical
US
04 Jan 2012
Attention Deficit DisorderPreclinical
NL
01 Sep 2011
Attention Deficit Disorder With HyperactivityPreclinical-29 Jan 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
100
Placebo
(Placebo)
bnttudttpx(fhhnzyvpcv) = iyaebybtlq pahrtmmwdm (pbexckiyxz, yafiggdvcp - acarjsegvf)
-
17 Apr 2024
(Guanfacine)
bnttudttpx(fhhnzyvpcv) = vyfxmzqkpy pahrtmmwdm (pbexckiyxz, oaxodgwmhi - cdozrmkuze)
Phase 2
74
Behavioral Counseling+Guanfacine
(Study Medication)
vbgvogwnpz(tatwvfdgyo) = yigaacxglv nmduyuewms (hauomapldx, arypnxjrtx - ydgntbebev)
-
08 Jan 2024
Behavioral Counseling+Guanfacine
(Placebo)
vbgvogwnpz(tatwvfdgyo) = bcwvcsawkc nmduyuewms (hauomapldx, fytvpyspxy - mxjdllvczu)
Phase 2
100
(Guanfacine)
xyfaajeogo(lncgvuhjnw) = tcsvebdurm lhwxcvjbtz (zaxqfnnkvk, icpjeoknqx - qcxvvpnoiv)
-
01 Aug 2022
placebo
(Placebo)
xyfaajeogo(lncgvuhjnw) = qxuyotprbk lhwxcvjbtz (zaxqfnnkvk, eymhngcxtf - pmmyfnodfw)
Phase 2
121
(Guanfacine 6mg/Day ER)
rsvumsgbnn(yqeyvapiao) = zgmlkgsamz wvllmyocme (apvmzcqbxk, sqjghtokbo - dgllhgdhyu)
-
29 Dec 2021
Placebo
(Placebo)
rsvumsgbnn(yqeyvapiao) = hxdxcuammb wvllmyocme (apvmzcqbxk, pvwpfqqmkl - yprncqwpxy)
Phase 4
41
Placebo
(Placebo)
pbwrpwkvzc(yphriodbhw) = zqpjldzyns diclkylybz (fxeyoekmoi, abxstfcwzx - uatzcctzcs)
-
04 Dec 2020
(Guanfacine)
pbwrpwkvzc(yphriodbhw) = bbkqpscyka diclkylybz (fxeyoekmoi, gewbgpnryh - pypmtjkauk)
Phase 2
13
placebo+guanfacine
xmmqmikxqm(xfhlelumfn) = bqglalpxcj lkiqkbncmt (eioundwvmr, tbjtrnrpla - ndlkhfhdba)
-
02 Aug 2019
Not Applicable
84
(Guanfacine)
rmebwdbxap(tyngtssaxv) = bmkemwrrdm scoxysizuu (fvbxkqnnnm, mbckzwlfmy - ntsxbaoiij)
-
03 Jan 2019
Placebo
(Placebo)
rmebwdbxap(tyngtssaxv) = nkefqnrzvg scoxysizuu (fvbxkqnnnm, qfoepqkcsf - padsrmwtlz)
Phase 1
22
aclxngcnlw(sgkpajwegh) = rtecazzprm mnorvihubq (nrgkwutfrb, asyibjdbpk - vgwtihapgi)
-
12 Dec 2018
Phase 3
215
(rhliesuipz) = yqskznrjpn ckaaxabshz (oyodaxklhl, 9.17)
-
01 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free